Editorial Type:
Article Category: Case Report
 | 
Online Publication Date: 08 Jul 2024

Use of Rocuronium and Sugammadex for a Patient With Controlled Polymyositis: A Case Report

DDS, PhD,
DDS,
DDS,
DDS, PhD,
DDS, PhD,
DDS, PhD, and
DDS, PhD
Page Range: 81 – 84
DOI: 10.2344/021627
Save
Download PDF

Muscle relaxants and their reverse drugs should be carefully administered to patients with acute polymyositis and/or dermatomyositis. However, the use of these drugs in controlled polymyositis and/or dermatomyositis is controversial. This case report describes the use of rocuronium and sugammadex in a 27-year-old female patient with controlled polymyositis who was scheduled for minor oral surgery under general anesthesia. General anesthesia was induced rapidly, and 0.66 mg/kg of rocuronium was administered prior to nasotracheal intubation. No additional muscle relaxants were administered during the surgery. At the end of surgery, approximately 2 hours after the rocuronium was administered, her train-of-four (TOF) ratio was still 49%. A dose of 3.3 mg/kg of sugammadex was administered, and it took 12 minutes for the TOF ratio to exceed 90%. The prolonged duration of muscle relaxation in patients with polymyositis may be due to a decrease in skeletal muscle and capillary volume. The slow onset of sugammadex may be caused by slow diffusion of rocuronium from the neuromuscular junction. Patients with polymyositis require close perioperative neuromuscular function monitoring, regardless of their disease control status.

Copyright: © 2024 by the American Dental Society of Anesthesiology

Contributor Notes

Drs Kuroda and Sanuki contributed equally to this work.

Address correspondence to Dr Hidetaka Kuroda, DDS, PhD, Department of Dental Anesthesiology, Kanagawa Dental University, 1-23 Ogawa-cho, Yokosuka, Kanagawa 2388570, Japan; kuroda@kdu.ac.jp.
Received: 30 Apr 2023
Accepted: 09 Oct 2023
  • Download PDF